TransMedics Group Inc (TMDX)

Currency in USD
118.79
-6.95(-5.53%)
Real-time Data·
TMDX Scorecard
Full Analysis
Net income is expected to grow this year
TMDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
116.62124.91
52 wk Range
55.00177.37
Key Statistics
Prev. Close
125.74
Open
124.91
Day's Range
116.62-124.91
52 wk Range
55-177.37
Volume
764.3K
Average Volume (3m)
1.1M
1-Year Change
-15.3%
Book Value / Share
9.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TMDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
142.29
Upside
+19.78%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

TransMedics Group Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

TransMedics Group Inc Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc SWOT Analysis


Organ Tech Pionee
TransMedics leads in organ transplant technology with its Organ Care System, driving a 109% year-over-year revenue increase and strong market position
Financial Trajectory
Explore TransMedics' fiscal projections, including 2024 revenue guidance of $428-$432 million and ambitious 2028 targets of $1.2 billion revenue
Market Dynamics
Delve into TransMedics' dominance in the DCD market and its strategic response to emerging competition from Getinge's acquisition of Paragonix
Innovation Pipeline
Discover TransMedics' plans for next-gen OCS Lung and Heart programs, digital platform updates, and expansion into new organ transplant segments
Read full SWOT analysis

TransMedics Group Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.92 beat expectations by 104.44%, revenue up 38% YoY to $157.4M
  • Stock rose 3.13% post-announcement, with 1.55% gain in aftermarket trading
  • Full-year revenue guidance raised to $585-$605M, targeting 35% YoY increase
  • U.S. transplant revenue grew 40% YoY; company aims for 30% operating margin by 2028
  • Exploring European market expansion; confident in heart and lung clinical trials growth
Last Updated: 31/07/2025, 00:02
Read Full Transcript

Compare TMDX to Peers and Sector

Metrics to compare
TMDX
Peers
Sector
Relationship
P/E Ratio
56.0x−3.4x−0.5x
PEG Ratio
0.03−0.340.00
Price/Book
12.6x2.5x2.6x
Price / LTM Sales
7.6x2.4x3.3x
Upside (Analyst Target)
15.2%85.0%42.8%
Fair Value Upside
Unlock9.1%6.5%Unlock

Analyst Ratings

6 Buy
3 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 142.29
(+19.78% Upside)

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
0.92 / 0.45
Revenue / Forecast
157.40M / 146.74M
EPS Revisions
Last 90 days

TMDX Income Statement

People Also Watch

14.38
OSCR
+4.05%
52.520
ASTS
-0.10%
44.020
RKLB
-1.63%
157.77
CRCL
+2.50%
50.94
HIMS
-8.25%

FAQ

What Stock Exchange Does TransMedics Trade On?

TransMedics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for TransMedics?

The stock symbol for TransMedics is "TMDX."

What Is the TransMedics Market Cap?

As of today, TransMedics market cap is 4.00B.

What Is TransMedics's Earnings Per Share (TTM)?

The TransMedics EPS (TTM) is 2.13.

When Is the Next TransMedics Earnings Date?

TransMedics will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is TMDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has TransMedics Stock Split?

TransMedics has split 0 times.

How Many Employees Does TransMedics Have?

TransMedics has 728 employees.

What is the current trading status of TransMedics (TMDX)?

As of 06 Aug 2025, TransMedics (TMDX) is trading at a price of 118.79, with a previous close of 125.74. The stock has fluctuated within a day range of 116.62 to 124.91, while its 52-week range spans from 55.00 to 177.37.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.